Will Medicaid Take More Than Its Fair Share Of Dual-Eligible Rebates?
Industry concerns that states are sometimes obtaining Medicaid drug rebates that are disproportionate to drug expenditures are unlikely to be allayed by CMS' recent proposed rules on Medicaid drug reimbursement
You may also be interested in...
CMS wants to include a broader array of pharmacy benefit manager price concessions in calculating Medicaid average manufacturer prices for reimbursing outpatient prescription drugs
In cases where costs for a physician-administered drug are shared by Medicaid and Medicare, manufacturers should only be required to pay rebates to states for the proportion paid for by Medicaid, Sen. Charles Grassley (R-Iowa) says in an Aug. 14 letter to CMS
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications